Long-term effects of stimulants on neurocognitive performance of Taiwanese children with attention-deficit/hyperactivity disorder

BMC Psychiatry

Shih-Ming Chu⁴  Ming-Horng Tsai⁴  Kin-Bao Young¹  Fang-Ming Hwang²  Chen-Long Wu⁶  Yu-Shu Huang³  Ching-Shu Tsai⁵ 

[1] Infant and Child Care Department, National Taipei University of Nursing and Health Science, Taipei, Taiwan;Department of Education, National Chia-Yi University, Chiayi, Taiwan;Department of Child Psychiatry, Chang Gung Memorial Hospital and University, Linkou, Taiwan;Department of Pediatrics, Division of Pediatric Neonatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan;Department of Psychiatry, Chang Gung Memorial Hospital and University, Chiayi, Taiwan;Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan

关键词: IQ;    WISC-III;    Intelligence;    Taiwan;    Attention-deficit/hyperactivity disorder;   

Others  :  1123866
DOI  :  10.1186/1471-244X-13-330

 received in 2012-11-24, accepted in 2013-11-26,  发布年份 2013

【 摘 要 】

Background

Attention-deficit/hyperactivity disorder (ADHD) is a common behavioral and neurocognitive disorder in school-age children. Methylphenidate (MPH) is the most frequently prescribed CNS stimulant for ADHD. The aim of this study is to evaluate the changes in intelligence quotient and domains of neurocognitive function after long-term MPH treatment of Taiwanese children with ADHD.

Methods

The Wechsler Intelligence Scale (WISC-III) was administrated twice at an interval of at least one year for all 171 subjects (6–12 years) and 47 age- and gender-matched children without ADHD. The ADHD-Rating scale and Clinical Global Impression-Severity (CGI-S) were also used at the time of enrolment, and at 6 months and one year later.

Results

Taiwanese children with ADHD had lower Verbal IQ (VIQ) and Full IQ (FIQ) and performed poorly on several subtests of the WISC-III, including Similarities, Vocabulary, and Coding, compared to healthy children without ADHD. After one year of MPH treatment, significant decrements in all scores of the ADHD-Rating scale and CGI-S and increments in several domains of the WISC-III, including FIQ, VIQ, PIQ, Perceptual Organization Index (POI), Picture Completion, Picture Arrangement, Object Assembly, and Digit Span were observed. When the ADHD children under MPH treatment were subdivided into two age groups (6–8 years and 9–12 years), significantly better performance in some subtests and subscales of the WISC-III (such as Similarities, Comprehension, and Object assembly) was found in the 6–8 years age group.

Conclusions

Long-term MPH treatment may improve the neurocognitive profiles of the ADHD children, as seen in their performance in several subtests and in the IQ scores on the WISC-III. And this improvement had no correlation with the decrement of ADHD symptoms. Starting stimulant treatment at as young an age as possible is advised due to the greater benefits in the 6–8 years age group, as seen in this study. More research in this area is also needed to confirm these results.

【 授权许可】

   
2013 Tsai et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Spencer TJ, Biederman J, Mick E: Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol 2007, 32:631-642.
• [2]APA: Diagnostic and statistical manual of mental disorders, DSM-IV-TR (text revision). 4th edition. Washington, DC: American Psychiatric Association; 2000.
• [3]Barkley RA: Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 2nd edition. New York: Guilford; 1998.
• [4]Tzang R-F, Wu K-H, Liou C-P: Prevalence of attention-deficit/hyperactivity disorder in a Taiwanese elementary school. Taiwanese J Psychiatry 2002, 16:202-212.
• [5]Gomez R, Harvey J, Quick C, Scharer I, Harris G: DSM-IV AD/HD: confirmatory factor models, prevalence, and gender and age differences based on parent and teacher ratings of Australian primary school children. J Child Psychol Psychiatry 1999, 40:265-274.
• [6]Robison LM, Sclar DA, Skaer TL, Galin RS: National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990–1995. Clin Pediatr (Phila) 1999, 38:209-217.
• [7]Barkley RA, DuPaul GJ, McMurray MB: Comprehensive evaluation of attention deficit disorder with and without hyperactivity as defined by research criteria. J Consult Clin Psychol 1990, 58:775-789.
• [8]Steele M, Jensen PS, Quinn DM: Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 2006, 28:1892-1908.
• [9]Zambrano-Sanchez E, Martinez-Cortes JA, Rio-Carlos YD, Martinez-Wbaldo Mdel C, Poblano A: Executive dysfunction screening and intelectual coefficient measurement in children with attention deficit hyperactivity disorder. Arq Neuropsiquiatr 2010, 68:545-549.
• [10]Frazier TW, Demaree HA, Youngstrom EA: Meta-analysis of intellectual and neuropsychological test performance in attention-deficit/hyperactivity disorder. Neuropsychology 2004, 18:543-555.
• [11]Zarin DA, Suarez AP, Pincus HA, Kupersanin E, Zito JM: Clinical and treatment characteristics of children with attention-deficit/hyperactivity disorder in psychiatric practice. J Am Acad Child Adolesc Psychiatry 1998, 37:1262-1270.
• [12]Overtoom CCE, Verbaten MN, Kemner C, Kenemans JL, Engeland H, Buitelaar JK, van der Molen MW, van der Gugten J, Westenberg H, Maes RAA, et al.: Effects of methylphenidate, desipramine, and l-dopa on attention and inhibition in children with attention deficit hyperactivity disorder. Behav Brain Res 2003, 145:7-15.
• [13]Jepsen JR, Fagerlund B, Mortensen EL: Do attention deficits influence IQ assessment in children and adolescents with ADHD? J Atten Disord 2009, 12:551-562.
• [14]Kavale K: The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis. J Learn Disabil 1982, 15:280-289.
• [15]Thurber S, Walker CE: Medication and hyperactivity: a meta-analysis. J Gen Psychol 1983, 108:79-86.
• [16]Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B, Eidevall-Wallin L, Gustafsson P, Kopp S: Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997, 54:857-864.
• [17]Gimpel GA, Collett BR, Veeder MA, Gifford JA, Sneddon P, Bushman B, Hughes K, Odell JD: Effects of stimulant medication on cognitive performance of children with ADHD. Clin Pediatr (Phila) 2005, 44:405-411.
• [18]Marco EM, Macri S, Laviola G: Critical age windows for neurodevelopmental psychiatric disorders: evidence from animal models. Neurotox Res 2011, 19:286-307.
• [19]Urban KR, Waterhouse BD, Gao WJ: Distinct age-dependent effects of methylphenidate on developing and adult prefrontal neurons. Biol Psychiatry 2012, 72:880-888.
• [20]Gronier B, Aston J, Liauzun C, Zetterstrom T: Age-dependent effects of methylphenidate in the prefrontal cortex: evidence from electrophysiological and Arc gene expression measurements. J Psychopharmacol 2010, 24:1819-1827.
• [21]Gau S-F, Suen Soong W-T: Psychiatric comorbidity of adolescents with sleep terrors or sleepwalking: a case–control study. Aust N Z J Psychiatry 1999, 33:734-739.
• [22]Chong M-Y, Chan K-W, Cheng ATA: Substance use disorders among adolescents in Taiwan: prevalence, sociodemographic correlates and psychiatric co-morbidity. Psychol Med 1999, 29:1387-1396.
• [23]Gau S-F, Chiu Y-N, Tsai W-C, Soong W-T: Average daily dose of methylphenidate for children with attention-deficit hyperactivity disorder in a medical center. Taiwanese J Psychiatry 2004, 18:136-141.
• [24]Wechsler D: Manual for the Wechsler intelligence scale for children (Chinese version). 3rd edition. San Antonio, TX: The Psychological Corporation; 1991.
• [25]Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation of the ADHD rating scale as a clirlician administered and scored instrument. J Atten Disord 2001, 5:107-115.
• [26]Guy W: ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
• [27]Mayes SD, Calhoun SL: Similarities and differences in Wechsler intelligence scale for children–third edition (WISC-III) profiles: support for subtest analysis in clinical referrals. Clin Neuropsychol 2004, 18:559-572.
• [28]Filippatou DN, Livaniou EA: Comorbidity and WISC-III profiles of Greek children with attention deficit hyperactivity disorder, learning disabilities, and language disorders. Psychol Rep 2005, 97:485-504.
• [29]Snow JB, Sapp GL: WISC-III subtest patterns of ADHD and normal samples. Psychol Rep 2000, 87:759-765.
• [30]Mayes SD, Calhoun SL: WISC-IV and WISC-III profiles in children with ADHD. J Atten Disord 2006, 9:486-493.
• [31]Swanson J, Baler RD, Volkow ND: Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology 2011, 36:207-226.
• [32]Hale JB, Reddy LA, Semrud-Clikeman M, Hain LA, Whitaker J, Morley J, Lawrence K, Smith A, Jones N: Executive impairment determines ADHD medication response: implications for academic achievement. J Learn Disabil 2011, 44:196-212.
• [33]Kubas HA, Backenson EM, Wilcox G, Piercy JC, Hale JB: The effects of methylphenidate on cognitive function in children with attention-deficit/hyperactivity disorder. Postgrad Med 2012, 124:33-48.
• [34]Pasini A, Sinibaldi L, Paloscia C, Douzgou S, Pitzianti MB, Romeo E, Curatolo P, Pizzuti A: Neurocognitive effects of methylphenidate on ADHD children with different DAT genotypes: A longitudinal open label trial. Eur J Paediatr Neurol 2013, 17:407-414.
• [35]Hellwig-Brida S, Daseking M, Keller F, Petermann F, Goldbeck L: Effects of methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011, 21:245-253.
• [36]Naglieri JA, Goldstein S, Delauder BY, Schwebach A: Relationships between the WISC-III and the cognitive assessment system with Conners’ rating scales and continuous performance tests. Arch Clin Neuropsychol 2005, 20:385-401.
• [37]Schuck SE, Crinella FM: Why children with ADHD do not have low IQs. J Learn Disabil 2005, 38:262-280.
• [38]Coghill DR, Rhodes SM, Matthews K: The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007, 62:954-962.
• [39]Konrad K, Gunther T, Heinzel-Gutenbrunner M, Herpertz-Dahlmann B: Clinical evaluation of subjective and objective changes in motor activity and attention in children with attention-deficit/hyperactivity disorder in a double-blind methylphenidate trial. J Child Adolesc Psychopharmacol 2005, 15:180-190.
• [40]Tang S-C, Chen M-Y, Chen C-T: The test-retest stability of the Wechsler intelligence scale for children-third edition. Arch Clin Psychol 2005, 2:41-48.